Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023

Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) to report 2023 second quarter financial results on August 9, 2023. Live webcast to discuss financial update and business performance.

DUBLIN, July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 second quarter financial results and provide a business and financial update.  

Audio webcast/conference call:
U.S. Dial-In Number: +1 833 470 1428
Ireland Dial-In Number: +353 1800 816 573
Additional global dial-in numbers are available here.
Passcode: 808512

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2023-second-quarter-financial-results-on-august-9-2023-301886520.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its 2023 second quarter financial results?

Jazz Pharmaceuticals will report its 2023 second quarter financial results on Wednesday, August 9, 2023, after the close of the U.S. financial markets.

How can I access the live audio webcast?

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.

What are the dial-in numbers for the audio webcast/conference call?

The U.S. Dial-In Number is +1 833 470 1428, and the Ireland Dial-In Number is +353 1800 816 573. Additional global dial-in numbers are available on the company's website.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.